Peptide–Drug Conjugate GnRH–Sunitinib Targets Angiogenesis Selectively at the Site of Action to Inhibit Tumor Growth
- 29 February 2016
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 76 (5) , 1181-1192
Abstract
The potential to heighten the efficacy of antiangiogenic agents was explored in this study based on active targeting of tumor cells overexpressing the gonadotropin-releasing hormone receptor (GnRH-R). The rational design pursued focused on five analogues of a clinically established antiangiogenic compound (sunitinib), from which a lead candidate (SAN1) was conjugated to the targeting peptide [d-Lys6]-GnRH, generating SAN1GSC. Conjugation of SAN1 did not disrupt any of its antiangiogenic or cytotoxic properties in GnRH-R–expressing prostate and breast tumor cells. Daily SAN1GSC treatments in mouse xenograft models of castration-resistant prostate cancer resulted in significant tumor growth delay compared with equimolar SAN1 or sunitinib alone. This efficacy correlated with inhibited phosphorylation of AKT and S6, together with reduced Ki-67 and CD31 expression. The superior efficacy of the peptide–drug conjugate was also attributed to the finding that higher amounts of SAN1 were delivered to the tumor site (∼4-fold) following dosing of SAN1GSC compared with equimolar amounts of nonconjugated SAN1. Importantly, treatment with SAN1GSC was associated with minimal hematotoxicity and cardiotoxicity based on measurements of the left ventricular systolic function in treated mice. Our results offer preclinical proof-of-concept for SAN1GSC as a novel molecule that selectively reaches the tumor site and downregulates angiogenesis with negligible cardiotoxicity, thus encouraging its further clinical development and evaluation. Cancer Res; 76(5); 1181–92. ©2015 AACR.Keywords
All Related Versions
This publication has 38 references indexed in Scilit:
- Design, Synthesis and Biological Evaluation of Sunitinib Analogues to Improve Aqueous SolubilityAdvanced Materials Research, 2013
- Coronary Microvascular Pericytes Are the Cellular Target of Sunitinib Malate–Induced CardiotoxicityScience Translational Medicine, 2013
- Synthesis, in silico, in vitro, and in vivo investigation of 5-[11C]methoxy-substituted sunitinib, a tyrosine kinase inhibitor of VEGFR-2European Journal of Medicinal Chemistry, 2012
- Detection of a rare BCR–ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS)Proceedings of the National Academy of Sciences, 2012
- Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancerRadiation Oncology, 2012
- First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III StudyJournal of Clinical Oncology, 2012
- New Insights into Molecular Mechanisms of Sunitinib-Associated Side EffectsMolecular Cancer Therapeutics, 2011
- Testosterone Suppresses Hepcidin in Men: A Potential Mechanism for Testosterone-Induced ErythrocytosisThe Journal of Clinical Endocrinology & Metabolism, 2010
- Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitorsBritish Journal of Cancer, 2009
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005